Current Research Studies
A PHASE II RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFECT OF GLCNAC ON TEAR PRODUCTION IN INDIVIDUALS WITH NGLY1-CDDG
NGLY-1 Trial
What is the goal of the study?
Patients with NGLY1-CDDG will be randomly assigned in a 1:1 ratio to receive either N-acetylglucosamine (GlcNAc) or placebo 3 times per day for 6 weeks. The primary efficacy endpoint is change in tear production between baseline and 6 weeks as measured by the Schirmer II test.
Who can participate in the study?
Please contact the study team listed below to learn more.